About Resverlogix
Resverlogix is a publicly listed company based in Calgary (Canada) founded in 2001. Selective BET-inhibitors for CV disease in diabetes patients are developed. Resverlogix has raised $115.9 million across 19 funding rounds from investors including Shenzhen Hepalink Pharmaceutical and Yorkville Advisors. The company has 18 employees. Resverlogix offers products and services including Apabetalone. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is Resverlogix Corp.
Company details
Resverlogix was founded in 2001 and is headquartered in Calgary, Canada. Operations are focused on the biopharmaceutical sector, where late-stage clinical development of small molecule BET-inhibitors targets cardiovascular disease in diabetes patients. The lead candidate, Apabetalone (RVX-208), is advanced as a selective bromodomain inhibitor for BRD4-BD2. A proprietary epigenetics platform supports drug discovery, with additional compounds identified for BET protein targeting.
- Headquarters Calgary, Canada
- Employees 18
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website resverlogix.com
- Social LinkedIn X
- Legal Name Resverlogix Corp.
- Net Profit-$7.92 M (USD)-3.76as on Dec 31, 2025
- EBITDA-$4.78 M (USD)-11.05as on Dec 31, 2025
- Total Equity Funding$115.9M (USD)
in 19 rounds
- Latest Funding Round$10M (USD), Post-IPO
Oct 2020
- InvestorsShenzhen Hepalink Pharmaceutical
& 1 more
- Employee Count18
Products & Services of Resverlogix
Resverlogix offers a comprehensive portfolio of products and services, including Apabetalone.
Epigenetic inhibitor for treating cardiovascular and chronic diseases.
Funding Insights of Resverlogix
Resverlogix has successfully raised a total of $115.9M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115.9M
- Total Rounds 19
- Last Round Post-IPO — $10M
- First Round $7.61M
(Jan 2010)
- Investors Count 2
Latest 10 of 19 funding rounds of Resverlogix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $10M | Post-IPO | – | – | – |
| Aug 2020 | $2M | Post-IPO | – | – | |
| Sep 2019 | $12M | Debt – Conventional | – | – | – |
| Jun 2019 | $11.2M | Post-IPO | – | – | – |
| Jan 2019 | $6.6M | Post-IPO | – | – | |
| Nov 2018 | $13.5M | Post-IPO | – | – | – |
| Sep 2018 | $19.95M | Post-IPO | – | – | – |
| Apr 2018 | $3.2M | Post-IPO | – | – | – |
| Dec 2017 | $87M | Post-IPO | – | – | |
| Jul 2015 | $50M | Private Equity Round | – | – |
2 investors in total: 2 institutional.
Investors in Resverlogix
Resverlogix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Shenzhen Hepalink Pharmaceutical and Yorkville Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Heparin Sodium API and derivatives are manufactured for global markets. | 1998 | hepalink.com | Shenzhen, China | |
Offers flexible capital to micro-cap and small-cap firms for growth. | 2001 | yorkvilleadvisors.com | Mountainside, United States |
Investor details for Resverlogix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Resverlogix
10 people are tracked at Resverlogix (4 in leadership, 4 in board & advisors, 2 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Donald J. McCaffrey | President & CEO | Leadership |
Ewelina Kulikowski | Chief Scientific Officer | Leadership |
Brad Cann | CFO | Leadership |
Michael Pack | VP Of Finance | Leadership |
Shawn Lu | Board Member | Board & advisors |
Kelly McNeill | Board Member | Board & advisors |
Dicky To | Board Member | Board & advisors |
Kenneth J. Zuerblis | Board Member | Board & advisors |
Michael Sweeney | SVP, Clinical Development | Team |
Katerina Stenvall | Financial Accountant | Team |
Complete people profiles for Resverlogix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Resverlogix
Resverlogix is a publicly listed company on the TSX with ticker symbol RVX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jan 2005
- Listed onTSX: RVX
- Listed entityResverlogix Corp.
- Exchange sectorHealth technology
- ISINCA76128M1086
- Share price0.09 CAD · 2026-10-13
- Market capitalisation29,264,371.00 CAD
- EPS (diluted, trailing year)-0.05 CAD
- Volume (last session)30,256
Financials of Resverlogix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -10.8M CAD | -6.5M CAD | |
| 2024 | -10.5M CAD | -5.9M CAD | |
| 2023 | -22.6M CAD | -7.5M CAD | |
| 2022 | -4.7M CAD | -15.4M CAD | |
| 2021 | -31.1M CAD | -18.7M CAD |
Detailed financial statements for Resverlogix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Resverlogix
4 dated milestones of Resverlogix across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Resverlogix is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.6M.
- Funding Latest funding round, Post-IPO, of $10.0M.
Web traffic of Resverlogix
The website of Resverlogix (resverlogix.com) receives about 4.7K visits a month and ranks #3,235,284 among all websites worldwide, #4,248 in Biotechnology and Pharmaceuticals.
- Monthly visits4.7K
▼ 20.2% vs previous month
- Unique visitors2.7K
per month
- Global rank#3,235,284
among all websites
- Category rank#4,248
Health · Biotechnology and Pharmaceuticals
- Bounce rate25%
- Pages per visit1.7
- Average visit23 sec
- DevicesDesktop 13% · Mobile 87%
Websites whose visitors overlap most with Resverlogix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| iris-pharma.com | 100% | 2.2K | #10,426,473 | View details | |
prainternational.com | prainternational.com | 100% | – | ||
novogen.com | novogen.com | 100% | – | ||
| incresearch.com | 100% | View details | |||
| nektar.com | 100% | 19.6K | #959,308 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Resverlogix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Resverlogix
Complete news archive for Resverlogix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Resverlogix
Resverlogix was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Resverlogix is headquartered in Calgary, Canada. It is registered at Calgary, Alberta, Canada.
Resverlogix is a funded company, having raised a total of $115.9M across 19 funding rounds to date. The company's 1st funding round was a Private Equity Round of $50M, raised on Jan 2010.
Resverlogix has 18 employees.
Resverlogix was founded in 2001 and is headquartered in Calgary, Canada. Operations are focused on the biopharmaceutical sector, where late-stage clinical development of small molecule BET-inhibitors targets cardiovascular disease in diabetes patients. The lead candidate, Apabetalone (RVX-208), is advanced as a selective bromodomain inhibitor for BRD4-BD2. A proprietary epigenetics platform supports drug discovery, with additional compounds identified for BET protein targeting.
Resverlogix offers Apabetalone.
Yes, Resverlogix is publicly traded on TSX under the ticker symbol RVX.
Resverlogix has 2 investors. Key investors include Shenzhen Hepalink Pharmaceutical, and Yorkville Advisors.
Resverlogix operates through Resverlogix Corp..